Paper Information

Title: 

INDICATION AND EFFECT OF IMMUNOSUPPRESSION THERAPY IN SECONDARY GLAUCOMA PATIENTS WITH UVEITIS

Type: PAPER
Author(s): ALI PANAHI R.*,MORSALI S.M.,SAYAHMELI SIMA
 
 *TABRIZ UNIVERSITY OF MEDICAL SCIENCES
 
Name of Seminar: BIENNIAL CONGRESS ON IMMUNOLOGY, ASTHMA AND ALLERGY
Type of Seminar:  CONGRESS
Sponsor:  IRAN UNIVERSITY OF MEDICAL SCIENCES AND HEALTH SERVICES
Date:  2007Volume 6
 
 
Abstract: 

PURPOSE: To assess the Indication and effect of immunosuppression therapy in Secondary glaucoma patients.
SETTING: Immunology and glaucoma Service, Department of Ophthalmology and Visual Sciences, Nickookary University Hospital.
METHODS: All consecutive patients with glaucoma secondary to uveitis and inadequate intraocular pressure (IOP) control (IOP >21 mm Hg) under maximum-tolerated medical therapy had immunosuppression. Eleven patients with active uveitis were treated. The etiology of the uveitis was recorded. The ocular variables were IOP, best corrected visual acuity, number of antiglaucoma medications, and complications. Success was defined as an IOP between 6 mm Hg and 21 mm Hg (inclusive) without medication (complete success), or with 1 or more antiglaucoma The mean follow-up was 45.9 ± 11.6 months (range 23 to 56 months).
RESULTS: immunosuppression therapy significantly reduced IOP from a mean baseline value of 35.1±7.0 mm Hg (range 23 to 48 mm Hg) to a mean final value of 18.1±4.9 mm Hg (range 12 to 30 mm Hg) (P<.0001). Complete success was achieved in 6 eyes (54.5%) and qualified success, in 10 eyes (90.9%). The mean number of pretreatment and final antiglaucoma medications was 3.4±0.8 (range 2 to 4) and 0.7±1.2 (range 0 to 3), respectively (P =.0004). Complications were minor and included transient hyphema and postoperative IOP spike.
CONCLUSION: This preliminary study suggests that immunosuppressant therapy is a safe, effective surgical alternative for treating glaucoma in patients with uveitis.

 
Keyword(s): 
 
Yearly Visit 16   tarjomyar
 
Latest on Blog
Enter SID Blog